aspirin + atenolol + hydrochlorothiazide + ACE inhibitor + statin

This five-component fixed-dose combination (polypill) or co-administered regimen was evaluated by The George Institute for Global Health for the primary and secondary prevention of cardiovascular disease (CVD). The intervention, specifically studied in the RAPCAPS (Rural Andhra Pradesh Cardiovascular Prevention Study) trial, combines an antiplatelet agent (aspirin), a beta-1 selective adrenergic receptor antagonist (atenolol), a thiazide diuretic (hydrochlorothiazide), an angiotensin-converting enzyme (ACE) inhibitor, and an HMG-CoA reductase inhibitor (statin). This strategy aims to simplify treatment regimens and improve adherence by simultaneously targeting multiple cardiovascular risk factors, including blood pressure, lipid levels, and platelet aggregation, particularly in resource-limited primary health care settings.

Other names

CVD PolypillGeorge Institute PolypillFixed-dose combination for CVD prevention